A5059131118- Neonatal Respiratory Health Research
- Neonatal and fetal brain pathology
- Infant Nutrition and Health
- Infant Development and Preterm Care
- Congenital Diaphragmatic Hernia Studies
- Fatty Acid Research and Health
- Hemophilia Treatment and Research
- Birth, Development, and Health
- Blood Coagulation and Thrombosis Mechanisms
- Neonatal Health and Biochemistry
- Biomedical Research and Pathophysiology
- Respiratory Support and Mechanisms
- Pharmaceutical studies and practices
- Venous Thromboembolism Diagnosis and Management
- Neurological Disorders and Treatments
- Fetal and Pediatric Neurological Disorders
- Cardiac Arrest and Resuscitation
- Medical and Biological Sciences
- Olfactory and Sensory Function Studies
- Dialysis and Renal Disease Management
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Trauma, Hemostasis, Coagulopathy, Resuscitation
- Childhood Cancer Survivors' Quality of Life
- Renal Diseases and Glomerulopathies
- Heparin-Induced Thrombocytopenia and Thrombosis
Université Laval
2018-2025
Centre hospitalier universitaire de Québec
2020-2025
Wilfrid Laurier University
2021-2025
University of Toronto
2019-2023
Hospital for Sick Children
2019-2023
Centre hospitalier de l'Université Laval
2023
SickKids Foundation
2019-2021
Canadian Paediatric Society
2020
Research Network (United States)
2020
Children's Hospital of Eastern Ontario
2018-2019
Abstract Bi-allelic loss-of-function variants in genes that encode subunits of the adaptor protein complex 4 (AP-4) lead to prototypical yet poorly understood forms childhood-onset and hereditary spastic paraplegia: SPG47 (AP4B1), SPG50 (AP4M1), SPG51 (AP4E1) SPG52 (AP4S1). Here, we report a detailed cross-sectional analysis clinical, imaging molecular data 156 patients from 101 families. Enrolled were diverse ethnic backgrounds covered wide age range (1.0–49.3 years). While mean at symptom...
Neonatal encephalopathy (NE) and hypoxic-ischemic (HIE) are linked to significant neurodevelopmental impairments. Magnetic resonance imaging (MRI) is the preferred modality for classifying brain injury severity in HIE, yet considerable variability exists among institutions terms of MRI timing, protocols, classification, scoring systems predicting long-term outcomes. A Canadian taskforce comprising radiologists neonatologists was established develop a consensus on optimal timing MRI,...
OBJECTIVES To determine whether maternal supplementation with high-dose docosahexaenoic acid (DHA) in breastfed, very preterm neonates improves neurodevelopmental outcomes at 18 to 22 months’ corrected age (CA). METHODS Planned follow-up of a randomized, double-blind, placebo-controlled, multicenter trial compare born before 29 weeks’ gestational (GA). Lactating mothers were randomized receive either DHA-rich algae oil or placebo within 72 hours delivery until 36 postmenstrual age....
To identify juvenile idiopathic arthritis (JIA) patients who developed IBD during treatment with anti-TNF-alpha agents and better characterize the clinical pathological presentation.A retrospective French multicentre study included a diagnosis of JIA according to ILAR criteria while under therapy before 18 years age. Intestinal biopsies were collected reviewed by same pathologist.Eight included. They had been treated etanercept from 11 78 months onset. Gastro-intestinal symptoms abdominal...
To examine the influence of timing initiation therapeutic hypothermia (TH) on brain injury MRI and neurodevelopmental outcomes at 18 months.
Oxylipins are derived from enzymatic and non-enzymatic oxidation of n-3 n-6 long-chain polyunsaturated fatty acids. They known to be involved in inflammatory processes. The aim this study was describe the breast milk oxylipin profile following a docosahexaenoic acid (DHA) supplementation mothers preterm infants. We examined oxylipins collected at day 14 post-delivery, 40 who delivered before 29 weeks gestation were supplemented with either DHA-rich algae oil (S-DHA) or placebo (PL). These...
Abstract Preterm infants are deficient in long-chain polyunsaturated fatty acids, especially docosahexaenoic acid (DHA), a (FA) associated with an increase bronchopulmonary dysplasia (BPD). In two previous randomized control trials, DHA supplementation did not reduce the risk of BPD. We examined breast milk FA profile, collected 14 days after birth, mothers who delivered before 29 weeks gestation and were supplemented DHA-rich algae oil or placebo within 72 h birth as part MOBYDIck trial....
<b><i>Introduction:</i></b> The aim of the study was to determine effect a maternal docosahexaenoic acid (DHA) supplementation during lactation, compared with placebo, on neonatal growth profile breastfed very preterm infants. <b><i>Methods:</i></b> Preterm infants’ profile, velocity from birth 36 weeks’ postmenstrual age (PMA), and at PMA were pre-specified secondary outcomes randomized placebo-controlled trial conducted in 16 Canadian...